ENABLE-2 News and media coverage

ENABLE-2 expands its portfolio with a British programme

ENABLE-2 welcomes a drug development programme led by Professor Christopher Schofield and Dr. Alistair Farley at the Ineos Oxford Institute for antimicrobial research (IOI), based at the University of Oxford.

"We are very happy that ENABLE-2 continues to consolidate its international presence with this promising programme," states Anders Karlén, Coordinator of ENABLE-2 and Professor of Computer-aided drug design at Uppsala University.

Research breakthrough in fight against resistant bacteria

Researchers at Uppsala University have identified a new class of antibiotics with potent activity against the multi-drug resistant bacteria that WHO pinpoints as the most critical to develop novel treatments for.

"That our compound can cure bloodstream infections in mice models indicates great potential," says Anders Karlén, Professor of Computer-aided drug design at the Department of Medicinal chemistry.

Chemistry Journal reporting from ENABLE-2 and the fight against resistent bacteria

The new issue of Swedish magazine Kemisk Tidskrift turns the spotlight on the rising threat posed by bacteria and the researchers leading the search for new weapons to fight antimicrobial resistance.

In the five page centerpiece, Professors Anders Karlén and Diarmaid Hughes talk about the ongoing work at antibiotic platform ENABLE-2.

ENABLE-2 expanding its project portfolio with two new programmes

Antibiotic platform ENABLE-2 welcomes two new programmes: the "Ornicidine" programme, a scientific collaboration between Leiden University (NL) and Queen's University Belfast (GB); and the "BamA Inhibitors" programme, based at Justus Liebig University Giessen and Fraunhofer IME (D).

“We are very happy with the great interest ENABLE-2 is generating in Europe, and we are raising our international presence to another level,” states Coordinator Anders Karlén.

ENABLE-2 funders

ENABLE-2 is supported by the Swedish Research Council, the National Research Programme on Antibiotic Resistance and Sweden's innovation agency Vinnova.